{"ticker": {"uuid": "468f0d07-c13a-49aa-ab99-ace36977a221", "symbol": "ALNY", "name": "Alnylam Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "US2043QAC1 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028 US2043QAC1 bond, traded on the Frankfurt Stock Exchange.", "url": "https://www.tradingview.com/symbols/FWB-US2043QAC1/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-22T05:40:26", "published_display": "22 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biomarker-collaboration-licensing-deals-report-162800336.html", "source_name": "GlobeNewswire", "published_at": "2026-07-21T16:28:00+00:00", "published_display": "21 Jul 2026 16:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Q2 2024 earnings summary", "summary": "Alnylam Pharmaceuticals (ALNY) reported strong Q2 2024 results, with net product revenues up 34% year-over-year to $410.1M and total revenues reaching $660M, a 107% increase. The company raised its 2024 net product revenue guidance to $1,575M\u2013$1,650M following positive Phase 3 st", "url": "https://quartr.com/events/alnylam-pharmaceuticals-inc-alny-q2-2024_ofiRo9Sj", "source_name": "Quartr", "published_at": "2026-07-21T12:11:41", "published_display": "21 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Stock And 2 US Health Care Names With Earnings In Focus", "summary": "This article examines Alnylam Pharmaceuticals (ALNY), Insulet (PODD), and Neurocrine Biosciences (NBIX), three U.S. large-cap health care stocks. It discusses their market positioning, financial outlook, and the balance of opportunities and risks they face amidst current market c", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-stock-and-2-us-health-care-names-with-earnings-in-fo", "source_name": "Simply Wall Street", "published_at": "2026-07-20T20:09:52", "published_display": "20 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Alnylam (ALNY) Turn Early Alzheimer\u2019s RNAi Signals Into a Durable Neuroscience Investment Story?", "summary": "Alnylam Pharmaceuticals (ALNY) recently presented positive Phase 1 and 2 updates for its RNAi candidate mivelsiran, targeting early-onset and Down syndrome-associated Alzheimer\u2019s disease, at AAIC 2026. The company reported long-term biomarker reductions and a favorable safety pro", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/can-alnylam-alny-turn-early-alzheimers-rnai-signals-into-a-d", "source_name": "Simply Wall Street", "published_at": "2026-07-19T10:39:37", "published_display": "19 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com", "summary": "Alnylam Pharmaceuticals (ALNY) stock has fallen to a 52-week low of $273.03, reflecting a 28.79% year-to-date and nearly 13% annual decline amidst biotechnology sector challenges. Despite the downturn, analysts maintain a bullish outlook with price targets up to $550, citing sign", "url": "https://ng.investing.com/news/stock-market-news/alnylam-pharmaceuticals-stock-hits-52week-low-at-27303-usd-93CH-2605484", "source_name": "Investing.com Nigeria", "published_at": "2026-07-18T14:11:32", "published_display": "18 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer\u2019s Pipeline Progresses", "summary": "Alnylam Pharmaceuticals (ALNY) recently initiated a Phase 2 trial for mivelsiran in Down syndrome-associated Alzheimer\u2019s, yet its stock price has declined by over 10% in the past week. Despite recent drops, the company is considered undervalued by analysts, trading at $267.47 aga", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as", "source_name": "Simply Wall Street", "published_at": "2026-07-18T03:11:41", "published_display": "18 Jul 2026 03:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Proxy filing Summary", "summary": "Alnylam Pharmaceuticals is holding its annual virtual meeting on May 20, 2026, where shareholders will vote on the election of three Class I directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026. The company reac", "url": "https://quartr.com/events/alnylam-pharmaceuticals-inc-alny-proxy-filing_ofiRFq2m", "source_name": "Quartr", "published_at": "2026-07-18T02:39:37", "published_display": "18 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam slips as recent analyst target cuts appear to overshadow pipeline updates ahead of earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNYTFLdXBLc2Rwbms1ZEZKdnBod0Z5ZmV2akVuLVNaVFFwSFdWUjBWdzBRRVdtc0s4enBaSndOWFEyVHEwVHZfbjZkdEw0clpLYTZ4VkFPYzlkZUNHd1UxYU8zUlpNWEw2aHY4ME1kS3dKYm1YVWZrcUhybnJwQS1sMHROMUJJSXY5M2M1bHBIbTMyT29uQ2RfUDlKVEJVOEc5REk2ZDdWR2UzQy1uVTJNSEdmRm1BRE5Gakxpc2dqVzNNaUN6c0tNdklWNmI?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T17:35:00+00:00", "published_display": "17 Jul 2026 17:35", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD", "summary": "Alnylam Pharmaceuticals (ALNY) stock has fallen to a 52-week low of $273.03, reflecting a nearly 29% year-to-date and 13% year-over-year decline due to biotechnology sector challenges. Despite this downturn, analysts maintain a bullish outlook with price targets up to $550, with ", "url": "https://www.investing.com/news/company-news/alnylam-pharmaceuticals-stock-hits-52week-low-at-27303-usd-93CH-4798813", "source_name": "Investing.com", "published_at": "2026-07-17T16:40:40", "published_display": "17 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQYk56Y2REQzE2VGt3Zk91OWo2cEtBNURzT2tXWk5vcUNGeDhoYzEwXzlrc3NzZkI4LWJjWW45ZmVIUHZoTlRYOTlsT1dfT1djb3pnNXdtM3hHMjRPd3oxLWR1ODdnVUZDQWJSTVlsQXdpZ1ZTa1c0OUVIY0R1TkdEWTFnOVNVMFVNdVA4MFNtSlRCMlBvWXhFU1hlSUhSRUhTZFlPWTlMbWR5Z1RYbU96MlhrQ0JJWHVXbUlRUkVvd0ZPX2k3NHZyMHk2NDZNVTdja0ttdHBJaWN6dUo2MWk4?oc=5", "source_name": "ChartMill", "published_at": "2026-07-17T08:10:32+00:00", "published_display": "17 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (ALNY) Price Events", "summary": "This article provides a quantitative analysis of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) focusing on liquidity mapping around price events. It highlights near-term weak sentiment, a significant risk-reward setup targeting a 17.9% gain versus 0.3% risk, and outlines three dist", "url": "https://news.stocktradersdaily.com/news_release/10/Liquidity_Mapping_Around_ALNY_Price_Events_071726024001_1784270401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T02:40:06", "published_display": "17 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results", "summary": "Alnylam Pharmaceuticals, Inc. announced it will report its Q2 2026 financial results on Thursday, July 30, 2026, before the U.S. markets open. Management will discuss these results and future expectations during a conference call and live audio webcast on the same day at 8:30 am ", "url": "https://www.biospace.com/press-releases/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-results", "source_name": "BioSpace", "published_at": "2026-07-17T01:40:41", "published_display": "17 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results", "summary": "Alnylam Pharmaceuticals (Nasdaq: ALNY) announced it will webcast a conference call on July 29, 2026, to discuss its second quarter 2026 financial results and provide a business update. The call will follow the release of its financial results that same day. Interested parties can", "url": "https://www.moomoo.com/news/post/73076536/press-release-alnylam-to-webcast-conference-call-discussing-second-quarter", "source_name": "Moomoo", "published_at": "2026-07-16T14:43:10", "published_display": "16 Jul 2026 14:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak", "summary": "Alnylam Pharmaceuticals (NASDAQ: ALNY) stock has experienced a significant downturn, dropping 14% and marking a five-day losing streak. This indicates a challenging period for the company's market performance.", "url": "https://www.trefis.com/data/companies/ALNY/no-login-required/QXooTQoA/Alnylam-Pharmaceuticals-Stock-In-Shambles-Down-14-With-5-Day-Losing-Streak", "source_name": "Trefis", "published_at": "2026-07-16T12:42:42", "published_display": "16 Jul 2026 12:42", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14%", "summary": "Alnylam Pharmaceuticals (ALNY) stock has experienced a significant downturn, falling 14% over five consecutive trading days, erasing $5.9 billion from its market value. Despite the biotech firm's impressive 82.6% revenue growth over the last year, its high price-to-earnings multi", "url": "https://www.trefis.com/stock/alny/articles/607509/alnylam-pharmaceuticals-stock-5-straight-red-days-down-14/2026-07-16", "source_name": "Trefis", "published_at": "2026-07-16T12:10:42", "published_display": "16 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns (NASDAQ:ALNY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQb09TTGR2LThITGdnYmdFNlVtQVRXck1EMHF2djJnNTlNZ09BaWxWTF9uelh4NFVTOFFEazlnOWw5ZG9uRnNqZUtZbzkwTVRNcWhhZG44aG5kQmJkZVowa215d3Q5QjlfajF6RmQyLXdNWHNsdmFhR190MmVfeXRSZ0tIdWNQUFFhVWlNdWJaWGZPOTExbDRHeC1QajBlT1N1LXVvZmJ0d3hiVEhhZjQwMjNEbmdmcURTZFQzWg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T09:44:13+00:00", "published_display": "16 Jul 2026 09:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease", "summary": "Alnylam Pharmaceuticals is advancing its neuroscience pipeline, highlighted at AAIC 2026, with RNAi therapeutics for neurological diseases. Key developments include the initiation of a Phase 2 study for mivelsiran in Down Syndrome-Associated Alzheimer\u2019s Disease and the completion", "url": "https://www.biospace.com/press-releases/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-showcasing-potential-of-rnai-in-neurological-disease", "source_name": "BioSpace", "published_at": "2026-07-15T14:43:10", "published_display": "15 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alnylam-initiates-mid-stage-study-103450179.html", "source_name": "MT Newswires", "published_at": "2026-07-15T10:34:50+00:00", "published_display": "15 Jul 2026 10:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises its Price Target on Alnylam (ALNY)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-raises-price-target-160956965.html", "source_name": "Insider Monkey", "published_at": "2026-07-14T16:09:56+00:00", "published_display": "14 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alnylam-pharmaceuticals-apos-q2-results-145035367.html", "source_name": "MT Newswires", "published_at": "2026-07-14T14:50:35+00:00", "published_display": "14 Jul 2026 14:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating", "summary": "BofA Securities has adjusted its price target for Alnylam Pharmaceuticals (ALNY) to $410, down from its previous target of $460, while reaffirming a Buy rating on the stock. This revision reflects an updated financial outlook for the company, indicating a moderated but still posi", "url": "https://www.moomoo.com/news/post/72935678/bofa-securities-cuts-alnylam-pharmaceuticals-price-target-to-410-from", "source_name": "Moomoo", "published_at": "2026-07-14T15:09:53", "published_display": "14 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALNY Maintained by B of A Securities -- Price Target Lowered to $410", "summary": "B of A Securities has maintained a 'Buy' rating for Alnylam Pharmaceuticals (ALNY) but lowered its price target from $460 to $410, a 10.87% decrease. Despite this, GuruFocus indicates ALNY is currently undervalued by 46.4%, with a GF Value\u2122 of $522.41 against a current price of $", "url": "https://www.gurufocus.com/news/8957935/alny-maintained-by-b-of-a-securities-price-target-lowered-to-410", "source_name": "GuruFocus", "published_at": "2026-07-14T15:09:53", "published_display": "14 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Price Target Raised to $485.00/Share From $470.00 by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has increased its price target for Alnylam Pharmaceuticals (ALNY) to $485.00 per share, up from the previous $470.00. This adjustment reflects the firm's updated valuation of the company's stock.", "url": "https://www.moomoo.com/news/post/72871219/alnylam-pharmaceuticals-price-target-raised-to-485-00-share-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T12:45:34", "published_display": "14 Jul 2026 12:45", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA cuts Alnylam stock price target on conservative outlook", "summary": "BofA Securities has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $460 to $410, while maintaining a Buy rating. This adjustment comes despite BofA's projections for Alnylam's second-quarter revenue exceeding consensus estimates for its key drugs. The fir", "url": "https://www.investing.com/news/analyst-ratings/bofa-cuts-alnylam-stock-price-target-on-conservative-outlook-93CH-4790387", "source_name": "Investing.com", "published_at": "2026-07-14T10:41:21", "published_display": "14 Jul 2026 10:41", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist cuts Alnylam stock price target to $410 on ATTR outlook", "summary": "Truist Securities has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) to $410 from $505, maintaining a Buy rating. This adjustment comes amidst increased uncertainty for the ATTR franchise's long-term growth outlook following a failed study by competitors, whic", "url": "https://www.investing.com/news/analyst-ratings/truist-cuts-alnylam-stock-price-target-to-410-on-attr-outlook-93CH-4788458", "source_name": "Investing.com", "published_at": "2026-07-13T13:39:46", "published_display": "13 Jul 2026 13:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Strong Buy Opportunity with 47% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPUmdJTU1kZ3dHNWE4djgyemN6R2M0cWg1RGlENWJKanBxblZ0VEYyZ3YxbE95aXFCZ0xWbC10cEdzZ3BCUkxhSnpRclAtRy0yRFJobHd0LUxJQ095REJDelQ3MnpGaFhxUEtYdFZiZmRpWnZMTVA2YW1WV0JObThxeXZUXzY1Ym9yNERVZmFoY2huWDRjVW1qUHM0MF9CbDdLZDdfRFhCQk9UM2YwRXR4cUJyNlUyVkRmZnQ4N1RDUnpnajl6R1F2TUxSNDZMOTBHMnZrc0ZjaHBPTUhh?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:06:55+00:00", "published_display": "13 Jul 2026 09:06", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How Investors May Respond To Alnylam Pharmaceuticals (ALNY) After Rival ATTR-CM Setback And New Partnerships", "summary": "Alnylam Pharmaceuticals (ALNY) is gaining investor attention following a rival's ATTR-CM therapy failure and its own strengthened commercial and AI partnerships. This improved competitive landscape for Alnylam, particularly for its TTR franchise and AMVUTTRA product, is expected ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/how-investors-may-respond-to-alnylam-pharmaceuticals-alny-af", "source_name": "Simply Wall Street", "published_at": "2026-07-12T13:10:42", "published_display": "12 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure", "summary": "Alnylam Pharmaceuticals (ALNY) surged after a competitor's transthyretin amyloid cardiomyopathy treatment failed a late-stage trial, shifting focus to Alnylam's ATTR portfolio. Despite a year-to-date share price decline of 21.84%, the stock is considered 28% undervalued by Simply", "url": "https://www.sahmcapital.com/news/content/alnylam-pharmaceuticals-alny-could-be-28-undervalued-following-rival-attr-trial-failure-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-12T00:09:46", "published_display": "12 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $400 to $468", "summary": "This article provides a quick overview of analyst ratings for Alnylam Pharmaceuticals (ALNY.US). Analysts have set price targets for the company between $400 and $468. The report gives investors a concise look at current market sentiment and future price expectations for ALNY.", "url": "https://www.moomoo.com/news/post/72784922/a-quick-look-at-today-s-ratings-for-alnylam-pharmaceuticals", "source_name": "Moomoo", "published_at": "2026-07-10T13:10:25", "published_display": "10 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRlpLemQ1NmllUk5HSy1DZ0JiZEFFOTh2cDM2eTMzZ3dmeDhsbVEtbC1pYWk2UFRaYXQ1dlVwYWhrWF9sOV83cmhIMDd6UllHeGtIZDVLYl92RWxSbmVtTXhtQzh1SHQtWFFLMUNBVXNGTV9sTHhKT3NMSEd6SGdTc1QzNlhJUnJBbTV2U2dLM2tfSUo4U1dMbWhpcmxxM3hsRFV6dDk3Y2s?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOQWdTdDlrb2Vyc3lIOTRmWnJsYi1RWkpwNElEeEtINGk1RFRNWFd5OVo0a3lVc0RubkhvYk0wMGN5UDFxbXFOaGt2STZaMXl2ZTkxTzFkdmhNdHJFeW44WkU5Ul9pbGtucjJ1c2VXRW02MllpdnF4RURjUmMtRHVFR0tmMkNuUjFoTEh4ZVB5NVlZUQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSjJTdF9OQXQ0Q2xQNDI3bFpXdjN5a2s4Q0ljc05XeTlRbjhzSDA5Zml6cnFMOGJGSGZSUjZFWFRlemN4dmZNQUtmS0FQMFlCV3hETEJVZnllNUUxLW9PNnpySjlxU0lhTy1mZ2o1ckh4a0loU3FrQlJGbEFWc3ZtRHJKVGtrU2Q2M1VaR2pqcUZHc0xrekljN3hrdmR5a1Uzc0ktaDVhTnA?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals, Inc. Stock 12\u2011Month Price Target Raised to $446.43, Implies 38% Upside", "summary": "Alnylam Pharmaceuticals, Inc.'s average 12-month stock price target has increased from $443.04 to $446.43, according to 23 analyst estimates, suggesting a potential 38% upside from its July 8 closing price. The consensus rating from 30 analysts remains \"Buy,\" with 22 buy ratings,", "url": "https://www.tradingview.com/news/tradingview:8b2b41396096a:0-alnylam-pharmaceuticals-inc-stock-12-month-price-target-raised-to-446-43-implies-38-upside/", "source_name": "TradingView", "published_at": "2026-07-10T00:39:46", "published_display": "10 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals focuses on RNAi pipeline as Nasdaq-listed biotech advances rare disease port", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOcHJ0WnBDNmJxeTlzTU1CMlhkckdJQlczZWU5RWJGSjU2Y0NqV0hYNVhBcTRsejBSN3k1cEM0VGpYbDJWUjFoSklPOXlHS1N4VXlYUl9ZVGx0NHliY1E0QTBQWHZYaDI1OGwxaDZPa3dGR3haU3JmQ1VNNUh4VU9WMnZuX0MxUEVsZVFqZHBjRm53OWVKRC04bW1mZWctcnR5N202bno1MlRJeUJrSmpSQnlpVG1jQXAtOFRGVGtXcEt5UnY3Y3BuVW53X2I?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T12:39:10+00:00", "published_display": "09 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (NASDAQ:ALNY): An Affordable Growth Stock with Explosive Momentum and a Reasonable Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPaURCR1lIbnZBN3N2SUNwMTJBQ1IwaVJ5WkFSZFpwQ2d5N0Z2TGlsdFc1Um1DZVZEN2ExcUxoUndYSmFneFBsbl9QTy1MWGdRR1ZyRlliOEx3NjNTWkNMWjFyX2FCVEFQOTdFV0RmX3JwME9RWkJZWWNOYmVNYzZ3WHdEWU14NklyZG1lay11RC1KZ1BOOU1qTlY5NXVpa3hqdXpnZEw1ellWTkw0LVdJbzRxSXdpUlBiT1hYZFVpV21IdHdKaWItdmsxcE9oSTR6ZkE2VGNDMkFQYkVEV3hZeGxwTTRjcEhKLV8wZUZmVVczdw?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQSjlKaHp1RmlSUnpZcUJLY1gxSS1yZzNlWDBSVE1qYTN5em1qLS1lSEw2TlNSbTFBaEVRU1BfWkdsb0syMk9NTVJLblBMZXdZZlRzWUd3SEJYV2R4U1pzNVo5UGMydnBtaVJmYi02dzdtbGNLTnFVU21zU19rSG9FOGlWSktITVI4NDNKZlhvNFZnUVo5MXNSNUdWQXlGQU5fbHZ2Q2JMVzJ5NFhnTDgtUi1HeTNLb2pRTVE2LWM2SWM2LUU0UjlIMWFsZkJaWmpKclJnNUtfMkFnVnJvZTJn?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI Collaboration Puts Alnylam\u2019s RNAi Pipeline Productivity In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY): Company Profile, Stock Price, News, Rankings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE1nNHd5eG9vT05heG5GbEJsdFFrcnI3Q3Vpcmh0Sks5Qk5POUNKbHVUcVF5LTltNzllcXhGR01LaHFSR1hJZmNkSlVGMVR4dW1laVJYUlJxQ0h4NEg0RXpqWFVR?oc=5", "source_name": "Fortune", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam director Pyott sells $1.15m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNU1BkNWI5cjdlVWFkaDZTRHBzaHZwUUpRUUZrYXR4QUtmb2tDeEN0cTFKVG5nblJhdGJNbFoxeTdIejRxcXpzdGFhbVRoUUMyNWxpVVVMeW4xWF92UkNuTHNWb1A2RVBTbFhfX0YzeHptWHlzUmNiS21GdkRQa0p0MVlieV9FY0JYSUd5OU0zcjNHUEtRNGFTbFhkVGFsMldINGhjRDlsWmtrdjQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Initiates Alnylam (ALNY) With Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQRkFrZWEyTUNJdEFFZmZZbVZYX29QUlhfRFhsbzFoRUFJRF8yblVmV3F3cThEd3BIZE5JYmNDQ0drMWhaWVNWRFdITDhuMUV6RHJMUG56UUgxZDhiNnFIUGxXTXJpWUtWa2pzSTRKV2VXSm9fbTZrZzIxS3hBU2h2NUx6RlBzMGlfWWZJR1BsTS1CVnV3TE8tUS1sVGk?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Time To Reconsider Alnylam Pharmaceuticals (ALNY) After Recent RNAi Progress And Volatile Price Moves", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOZWVPZ01fbWJBVUdUcHBhZXpJOXRKUWJ5Rml4RkpXOEFWR3dRVTZ4Ym1YZ2pGTlRYS3RudGNXc3BydGd1ajFDdTRoNzV0ajVUUzg1SVZydEtlRUFXcU85MTlHWHd4MmwwaHBoblVCWUtRWEd0WlJnRVpDajk4cVhxN2J2dU1uVS04QWE2MjdaUXY4azNoaGRSc2pfcXp2dU1LSnBNa3ktaFB3NjJ3?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bernstein SocGen lowers Alnylam stock price target on valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOc0w2REtTVU9LZzZXei1BU0tWNWRzZ1dWZFZiLVZ0eTUwRzM4dTZ5Qzk2NnA5VmpOTXdhajNuOHFLRVI2VWZMcEdGUTl3Y2g1TnQwZTFZQWlIZFFucUNRVVY5QUdJRXhOTE44aWFUMUpuYWNSRDlURFY1eWhPN0EyS25LM3c2VUkyT0NDUmEtQ0tiN2JheXVRUnpfYWRmbm5rNTV4RHNmRU1ERlRqcVVIV0R3bW1LYUszSzMyc1RaUS0?oc=5", "source_name": "Investing.com", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Earnings Turn To Profitability Challenges Premium P/E Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQTlEyVjFyUC1qZkUzcXJqVW1xOVNCZXZ3QmlXNkNsaTJiWGhkdDc1Q2cwSXVxbDBRcjRBbzZ3TWhoRG00LU00V2RYTlM3bUFUZkxCclhHdzNrSEZYcWU2Y1dZZEVoMzZ3WWZhYko3ZzA3N2pONnpjd3UtaXUtTnRqTDgyM2txWlUwTFE0bTc2ejdPSV84WUl1TTZER21qNUJRbEpRZjBydEV3eVJN?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam (ALNY) slides 4% as valuation concerns linger after recent analyst reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQVE1TcFRfQVc3Si14WnlOOU55a1VIQUN4X0NCdzZHdzZLbTJGZUpkWm9xczFUZ3hIY3dYbTRTYXpzWU9NMGwtUFI2TlgtRDA0OTFwTGhVQUxZWFFJcmhhb2Nfa2JURVBYT1BoTkU0ei1VcjVKUHMxRW54Wm1ObTNYTnh6OVI4eXRKYk9rSTgxVFJIYVdUd3c0cnJ5NHlobW1XaENCTHFVV0RTMHRZQmdqOWUycGRuUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxObVJSVEEzY1NnaHZfZXJpTXJtQWZVV21TMWtWUU4wVkxMcUp3QjFVc3BXeFVPd2lVVGxtVm5jWW9GanBNc1BzcE91MkUwRkl5b19PVFk2UW9ianAyd2dWNmxONERfSjlQSEs1NV9saDhxNy1ZRFA4NFdJck42UVZySU9zLTI2WXVuaTNTSnBZVGNLZFY0LThwRFM3Nnltb2F6N2tadm9wVDBfc3EycWc?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQM0ZQNFJJNGh4cnlyQ1V2aVp4amdWZ013LWhQR3JuSkFVbnFqcXd1REVFRG5TM2wteTRsem1zU0g5M0hyX2Q3SXpQYkhfU1E4czhkMG85U1I0WktHR2xuNjN3bjFzNGtyQTJqQnJ0amFBcEZBV2FWVXZPYUJMSUdzZzQxRnpvYlhzOGRpT3ZHZEp6VTFxNGpCWXFaSnpmaG93OXE1cDRYYXF4T1EtQUtXVUpXNEU4YkZGYlR2R1lGSXJzd29wSE1TN0VZOXZnblFuenNZYjM5NUM?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOamVIbzhDaGtBU3NFOVhYRndfaExDY3pTMUNRVDd1d1Q0SE9qOWpEcUxvNWktU281ZVpPN3lfOEhybjROcXZxdHdjWFlUSUw3WG5EY1JReW9kTnpOSUJuak8tMEpBampWYUxUeW10RWdjR2x1d1dXWjVidm9NRUhoalB1amxQWkF6eE1PQWFDZFo?oc=5", "source_name": "Market source", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNR0ZOMzF5TjJzbTdMd3N5cWd5ZGtOckVwdXo0WkxhWE5EMjNGSkloMzllZDJJSEdMd0ZpX296RmF1RHA1aFhSUjZpTUpxSTFGcW16VXFlbGpEalpLbVJLSVhPRlVCMnFneGhCN2RJVVV1Z1M1aDhNSU93VkMzV0hBTE1BOG5JY0Z3cDNRSlA5UklGSVhaMW9OOS1xbG5YQQ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "US2043QAC1 Bond Profile \u2014 Key Metrics", "summary": "This article provides key metrics for the Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028 US2043QAC1 bond, traded on the Frankfurt Stock Exchange.", "url": "https://www.tradingview.com/symbols/FWB-US2043QAC1/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-22T05:40:26", "published_display": "22 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biomarker-collaboration-licensing-deals-report-162800336.html", "source_name": "GlobeNewswire", "published_at": "2026-07-21T16:28:00+00:00", "published_display": "21 Jul 2026 16:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Q2 2024 earnings summary", "summary": "Alnylam Pharmaceuticals (ALNY) reported strong Q2 2024 results, with net product revenues up 34% year-over-year to $410.1M and total revenues reaching $660M, a 107% increase. The company raised its 2024 net product revenue guidance to $1,575M\u2013$1,650M following positive Phase 3 st", "url": "https://quartr.com/events/alnylam-pharmaceuticals-inc-alny-q2-2024_ofiRo9Sj", "source_name": "Quartr", "published_at": "2026-07-21T12:11:41", "published_display": "21 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Stock And 2 US Health Care Names With Earnings In Focus", "summary": "This article examines Alnylam Pharmaceuticals (ALNY), Insulet (PODD), and Neurocrine Biosciences (NBIX), three U.S. large-cap health care stocks. It discusses their market positioning, financial outlook, and the balance of opportunities and risks they face amidst current market c", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-stock-and-2-us-health-care-names-with-earnings-in-fo", "source_name": "Simply Wall Street", "published_at": "2026-07-20T20:09:52", "published_display": "20 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Alnylam (ALNY) Turn Early Alzheimer\u2019s RNAi Signals Into a Durable Neuroscience Investment Story?", "summary": "Alnylam Pharmaceuticals (ALNY) recently presented positive Phase 1 and 2 updates for its RNAi candidate mivelsiran, targeting early-onset and Down syndrome-associated Alzheimer\u2019s disease, at AAIC 2026. The company reported long-term biomarker reductions and a favorable safety pro", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/can-alnylam-alny-turn-early-alzheimers-rnai-signals-into-a-d", "source_name": "Simply Wall Street", "published_at": "2026-07-19T10:39:37", "published_display": "19 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com", "summary": "Alnylam Pharmaceuticals (ALNY) stock has fallen to a 52-week low of $273.03, reflecting a 28.79% year-to-date and nearly 13% annual decline amidst biotechnology sector challenges. Despite the downturn, analysts maintain a bullish outlook with price targets up to $550, citing sign", "url": "https://ng.investing.com/news/stock-market-news/alnylam-pharmaceuticals-stock-hits-52week-low-at-27303-usd-93CH-2605484", "source_name": "Investing.com Nigeria", "published_at": "2026-07-18T14:11:32", "published_display": "18 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer\u2019s Pipeline Progresses", "summary": "Alnylam Pharmaceuticals (ALNY) recently initiated a Phase 2 trial for mivelsiran in Down syndrome-associated Alzheimer\u2019s, yet its stock price has declined by over 10% in the past week. Despite recent drops, the company is considered undervalued by analysts, trading at $267.47 aga", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-could-be-39-below-fair-value-as", "source_name": "Simply Wall Street", "published_at": "2026-07-18T03:11:41", "published_display": "18 Jul 2026 03:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Proxy filing Summary", "summary": "Alnylam Pharmaceuticals is holding its annual virtual meeting on May 20, 2026, where shareholders will vote on the election of three Class I directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for 2026. The company reac", "url": "https://quartr.com/events/alnylam-pharmaceuticals-inc-alny-proxy-filing_ofiRFq2m", "source_name": "Quartr", "published_at": "2026-07-18T02:39:37", "published_display": "18 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam slips as recent analyst target cuts appear to overshadow pipeline updates ahead of earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNYTFLdXBLc2Rwbms1ZEZKdnBod0Z5ZmV2akVuLVNaVFFwSFdWUjBWdzBRRVdtc0s4enBaSndOWFEyVHEwVHZfbjZkdEw0clpLYTZ4VkFPYzlkZUNHd1UxYU8zUlpNWEw2aHY4ME1kS3dKYm1YVWZrcUhybnJwQS1sMHROMUJJSXY5M2M1bHBIbTMyT29uQ2RfUDlKVEJVOEc5REk2ZDdWR2UzQy1uVTJNSEdmRm1BRE5Gakxpc2dqVzNNaUN6c0tNdklWNmI?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T17:35:00+00:00", "published_display": "17 Jul 2026 17:35", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD", "summary": "Alnylam Pharmaceuticals (ALNY) stock has fallen to a 52-week low of $273.03, reflecting a nearly 29% year-to-date and 13% year-over-year decline due to biotechnology sector challenges. Despite this downturn, analysts maintain a bullish outlook with price targets up to $550, with ", "url": "https://www.investing.com/news/company-news/alnylam-pharmaceuticals-stock-hits-52week-low-at-27303-usd-93CH-4798813", "source_name": "Investing.com", "published_at": "2026-07-17T16:40:40", "published_display": "17 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQYk56Y2REQzE2VGt3Zk91OWo2cEtBNURzT2tXWk5vcUNGeDhoYzEwXzlrc3NzZkI4LWJjWW45ZmVIUHZoTlRYOTlsT1dfT1djb3pnNXdtM3hHMjRPd3oxLWR1ODdnVUZDQWJSTVlsQXdpZ1ZTa1c0OUVIY0R1TkdEWTFnOVNVMFVNdVA4MFNtSlRCMlBvWXhFU1hlSUhSRUhTZFlPWTlMbWR5Z1RYbU96MlhrQ0JJWHVXbUlRUkVvd0ZPX2k3NHZyMHk2NDZNVTdja0ttdHBJaWN6dUo2MWk4?oc=5", "source_name": "ChartMill", "published_at": "2026-07-17T08:10:32+00:00", "published_display": "17 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (ALNY) Price Events", "summary": "This article provides a quantitative analysis of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) focusing on liquidity mapping around price events. It highlights near-term weak sentiment, a significant risk-reward setup targeting a 17.9% gain versus 0.3% risk, and outlines three dist", "url": "https://news.stocktradersdaily.com/news_release/10/Liquidity_Mapping_Around_ALNY_Price_Events_071726024001_1784270401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-17T02:40:06", "published_display": "17 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results", "summary": "Alnylam Pharmaceuticals, Inc. announced it will report its Q2 2026 financial results on Thursday, July 30, 2026, before the U.S. markets open. Management will discuss these results and future expectations during a conference call and live audio webcast on the same day at 8:30 am ", "url": "https://www.biospace.com/press-releases/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-results", "source_name": "BioSpace", "published_at": "2026-07-17T01:40:41", "published_display": "17 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results", "summary": "Alnylam Pharmaceuticals (Nasdaq: ALNY) announced it will webcast a conference call on July 29, 2026, to discuss its second quarter 2026 financial results and provide a business update. The call will follow the release of its financial results that same day. Interested parties can", "url": "https://www.moomoo.com/news/post/73076536/press-release-alnylam-to-webcast-conference-call-discussing-second-quarter", "source_name": "Moomoo", "published_at": "2026-07-16T14:43:10", "published_display": "16 Jul 2026 14:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak", "summary": "Alnylam Pharmaceuticals (NASDAQ: ALNY) stock has experienced a significant downturn, dropping 14% and marking a five-day losing streak. This indicates a challenging period for the company's market performance.", "url": "https://www.trefis.com/data/companies/ALNY/no-login-required/QXooTQoA/Alnylam-Pharmaceuticals-Stock-In-Shambles-Down-14-With-5-Day-Losing-Streak", "source_name": "Trefis", "published_at": "2026-07-16T12:42:42", "published_display": "16 Jul 2026 12:42", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14%", "summary": "Alnylam Pharmaceuticals (ALNY) stock has experienced a significant downturn, falling 14% over five consecutive trading days, erasing $5.9 billion from its market value. Despite the biotech firm's impressive 82.6% revenue growth over the last year, its high price-to-earnings multi", "url": "https://www.trefis.com/stock/alny/articles/607509/alnylam-pharmaceuticals-stock-5-straight-red-days-down-14/2026-07-16", "source_name": "Trefis", "published_at": "2026-07-16T12:10:42", "published_display": "16 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns (NASDAQ:ALNY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQb09TTGR2LThITGdnYmdFNlVtQVRXck1EMHF2djJnNTlNZ09BaWxWTF9uelh4NFVTOFFEazlnOWw5ZG9uRnNqZUtZbzkwTVRNcWhhZG44aG5kQmJkZVowa215d3Q5QjlfajF6RmQyLXdNWHNsdmFhR190MmVfeXRSZ0tIdWNQUFFhVWlNdWJaWGZPOTExbDRHeC1QajBlT1N1LXVvZmJ0d3hiVEhhZjQwMjNEbmdmcURTZFQzWg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-16T09:44:13+00:00", "published_display": "16 Jul 2026 09:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease", "summary": "Alnylam Pharmaceuticals is advancing its neuroscience pipeline, highlighted at AAIC 2026, with RNAi therapeutics for neurological diseases. Key developments include the initiation of a Phase 2 study for mivelsiran in Down Syndrome-Associated Alzheimer\u2019s Disease and the completion", "url": "https://www.biospace.com/press-releases/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-showcasing-potential-of-rnai-in-neurological-disease", "source_name": "BioSpace", "published_at": "2026-07-15T14:43:10", "published_display": "15 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alnylam-initiates-mid-stage-study-103450179.html", "source_name": "MT Newswires", "published_at": "2026-07-15T10:34:50+00:00", "published_display": "15 Jul 2026 10:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises its Price Target on Alnylam (ALNY)", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-raises-price-target-160956965.html", "source_name": "Insider Monkey", "published_at": "2026-07-14T16:09:56+00:00", "published_display": "14 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alnylam-pharmaceuticals-apos-q2-results-145035367.html", "source_name": "MT Newswires", "published_at": "2026-07-14T14:50:35+00:00", "published_display": "14 Jul 2026 14:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating", "summary": "BofA Securities has adjusted its price target for Alnylam Pharmaceuticals (ALNY) to $410, down from its previous target of $460, while reaffirming a Buy rating on the stock. This revision reflects an updated financial outlook for the company, indicating a moderated but still posi", "url": "https://www.moomoo.com/news/post/72935678/bofa-securities-cuts-alnylam-pharmaceuticals-price-target-to-410-from", "source_name": "Moomoo", "published_at": "2026-07-14T15:09:53", "published_display": "14 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALNY Maintained by B of A Securities -- Price Target Lowered to $410", "summary": "B of A Securities has maintained a 'Buy' rating for Alnylam Pharmaceuticals (ALNY) but lowered its price target from $460 to $410, a 10.87% decrease. Despite this, GuruFocus indicates ALNY is currently undervalued by 46.4%, with a GF Value\u2122 of $522.41 against a current price of $", "url": "https://www.gurufocus.com/news/8957935/alny-maintained-by-b-of-a-securities-price-target-lowered-to-410", "source_name": "GuruFocus", "published_at": "2026-07-14T15:09:53", "published_display": "14 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals Price Target Raised to $485.00/Share From $470.00 by HC Wainwright & Co.", "summary": "HC Wainwright & Co. has increased its price target for Alnylam Pharmaceuticals (ALNY) to $485.00 per share, up from the previous $470.00. This adjustment reflects the firm's updated valuation of the company's stock.", "url": "https://www.moomoo.com/news/post/72871219/alnylam-pharmaceuticals-price-target-raised-to-485-00-share-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T12:45:34", "published_display": "14 Jul 2026 12:45", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA cuts Alnylam stock price target on conservative outlook", "summary": "BofA Securities has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $460 to $410, while maintaining a Buy rating. This adjustment comes despite BofA's projections for Alnylam's second-quarter revenue exceeding consensus estimates for its key drugs. The fir", "url": "https://www.investing.com/news/analyst-ratings/bofa-cuts-alnylam-stock-price-target-on-conservative-outlook-93CH-4790387", "source_name": "Investing.com", "published_at": "2026-07-14T10:41:21", "published_display": "14 Jul 2026 10:41", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist cuts Alnylam stock price target to $410 on ATTR outlook", "summary": "Truist Securities has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) to $410 from $505, maintaining a Buy rating. This adjustment comes amidst increased uncertainty for the ATTR franchise's long-term growth outlook following a failed study by competitors, whic", "url": "https://www.investing.com/news/analyst-ratings/truist-cuts-alnylam-stock-price-target-to-410-on-attr-outlook-93CH-4788458", "source_name": "Investing.com", "published_at": "2026-07-13T13:39:46", "published_display": "13 Jul 2026 13:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Strong Buy Opportunity with 47% Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPUmdJTU1kZ3dHNWE4djgyemN6R2M0cWg1RGlENWJKanBxblZ0VEYyZ3YxbE95aXFCZ0xWbC10cEdzZ3BCUkxhSnpRclAtRy0yRFJobHd0LUxJQ095REJDelQ3MnpGaFhxUEtYdFZiZmRpWnZMTVA2YW1WV0JObThxeXZUXzY1Ym9yNERVZmFoY2huWDRjVW1qUHM0MF9CbDdLZDdfRFhCQk9UM2YwRXR4cUJyNlUyVkRmZnQ4N1RDUnpnajl6R1F2TUxSNDZMOTBHMnZrc0ZjaHBPTUhh?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:06:55+00:00", "published_display": "13 Jul 2026 09:06", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Alnylam Pharmaceuticals (ALNY) After Rival ATTR-CM Setback And New Partnerships", "summary": "Alnylam Pharmaceuticals (ALNY) is gaining investor attention following a rival's ATTR-CM therapy failure and its own strengthened commercial and AI partnerships. This improved competitive landscape for Alnylam, particularly for its TTR franchise and AMVUTTRA product, is expected ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/how-investors-may-respond-to-alnylam-pharmaceuticals-alny-af", "source_name": "Simply Wall Street", "published_at": "2026-07-12T13:10:42", "published_display": "12 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure", "summary": "Alnylam Pharmaceuticals (ALNY) surged after a competitor's transthyretin amyloid cardiomyopathy treatment failed a late-stage trial, shifting focus to Alnylam's ATTR portfolio. Despite a year-to-date share price decline of 21.84%, the stock is considered 28% undervalued by Simply", "url": "https://www.sahmcapital.com/news/content/alnylam-pharmaceuticals-alny-could-be-28-undervalued-following-rival-attr-trial-failure-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-12T00:09:46", "published_display": "12 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $400 to $468", "summary": "This article provides a quick overview of analyst ratings for Alnylam Pharmaceuticals (ALNY.US). Analysts have set price targets for the company between $400 and $468. The report gives investors a concise look at current market sentiment and future price expectations for ALNY.", "url": "https://www.moomoo.com/news/post/72784922/a-quick-look-at-today-s-ratings-for-alnylam-pharmaceuticals", "source_name": "Moomoo", "published_at": "2026-07-10T13:10:25", "published_display": "10 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Stock Looks Rich On Earnings Yet Strong On Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRlpLemQ1NmllUk5HSy1DZ0JiZEFFOTh2cDM2eTMzZ3dmeDhsbVEtbC1pYWk2UFRaYXQ1dlVwYWhrWF9sOV83cmhIMDd6UllHeGtIZDVLYl92RWxSbmVtTXhtQzh1SHQtWFFLMUNBVXNGTV9sTHhKT3NMSEd6SGdTc1QzNlhJUnJBbTV2U2dLM2tfSUo4U1dMbWhpcmxxM3hsRFV6dDk3Y2s?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOQWdTdDlrb2Vyc3lIOTRmWnJsYi1RWkpwNElEeEtINGk1RFRNWFd5OVo0a3lVc0RubkhvYk0wMGN5UDFxbXFOaGt2STZaMXl2ZTkxTzFkdmhNdHJFeW44WkU5Ul9pbGtucjJ1c2VXRW02MllpdnF4RURjUmMtRHVFR0tmMkNuUjFoTEh4ZVB5NVlZUQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSjJTdF9OQXQ0Q2xQNDI3bFpXdjN5a2s4Q0ljc05XeTlRbjhzSDA5Zml6cnFMOGJGSGZSUjZFWFRlemN4dmZNQUtmS0FQMFlCV3hETEJVZnllNUUxLW9PNnpySjlxU0lhTy1mZ2o1ckh4a0loU3FrQlJGbEFWc3ZtRHJKVGtrU2Q2M1VaR2pqcUZHc0xrekljN3hrdmR5a1Uzc0ktaDVhTnA?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals, Inc. Stock 12\u2011Month Price Target Raised to $446.43, Implies 38% Upside", "summary": "Alnylam Pharmaceuticals, Inc.'s average 12-month stock price target has increased from $443.04 to $446.43, according to 23 analyst estimates, suggesting a potential 38% upside from its July 8 closing price. The consensus rating from 30 analysts remains \"Buy,\" with 22 buy ratings,", "url": "https://www.tradingview.com/news/tradingview:8b2b41396096a:0-alnylam-pharmaceuticals-inc-stock-12-month-price-target-raised-to-446-43-implies-38-upside/", "source_name": "TradingView", "published_at": "2026-07-10T00:39:46", "published_display": "10 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals focuses on RNAi pipeline as Nasdaq-listed biotech advances rare disease port", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOcHJ0WnBDNmJxeTlzTU1CMlhkckdJQlczZWU5RWJGSjU2Y0NqV0hYNVhBcTRsejBSN3k1cEM0VGpYbDJWUjFoSklPOXlHS1N4VXlYUl9ZVGx0NHliY1E0QTBQWHZYaDI1OGwxaDZPa3dGR3haU3JmQ1VNNUh4VU9WMnZuX0MxUEVsZVFqZHBjRm53OWVKRC04bW1mZWctcnR5N202bno1MlRJeUJrSmpSQnlpVG1jQXAtOFRGVGtXcEt5UnY3Y3BuVW53X2I?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T12:39:10+00:00", "published_display": "09 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (NASDAQ:ALNY): An Affordable Growth Stock with Explosive Momentum and a Reasonable Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxPaURCR1lIbnZBN3N2SUNwMTJBQ1IwaVJ5WkFSZFpwQ2d5N0Z2TGlsdFc1Um1DZVZEN2ExcUxoUndYSmFneFBsbl9QTy1MWGdRR1ZyRlliOEx3NjNTWkNMWjFyX2FCVEFQOTdFV0RmX3JwME9RWkJZWWNOYmVNYzZ3WHdEWU14NklyZG1lay11RC1KZ1BOOU1qTlY5NXVpa3hqdXpnZEw1ellWTkw0LVdJbzRxSXdpUlBiT1hYZFVpV21IdHdKaWItdmsxcE9oSTR6ZkE2VGNDMkFQYkVEV3hZeGxwTTRjcEhKLV8wZUZmVVczdw?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQSjlKaHp1RmlSUnpZcUJLY1gxSS1yZzNlWDBSVE1qYTN5em1qLS1lSEw2TlNSbTFBaEVRU1BfWkdsb0syMk9NTVJLblBMZXdZZlRzWUd3SEJYV2R4U1pzNVo5UGMydnBtaVJmYi02dzdtbGNLTnFVU21zU19rSG9FOGlWSktITVI4NDNKZlhvNFZnUVo5MXNSNUdWQXlGQU5fbHZ2Q2JMVzJ5NFhnTDgtUi1HeTNLb2pRTVE2LWM2SWM2LUU0UjlIMWFsZkJaWmpKclJnNUtfMkFnVnJvZTJn?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI Collaboration Puts Alnylam\u2019s RNAi Pipeline Productivity In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY): Company Profile, Stock Price, News, Rankings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE1nNHd5eG9vT05heG5GbEJsdFFrcnI3Q3Vpcmh0Sks5Qk5POUNKbHVUcVF5LTltNzllcXhGR01LaHFSR1hJZmNkSlVGMVR4dW1laVJYUlJxQ0h4NEg0RXpqWFVR?oc=5", "source_name": "Fortune", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam director Pyott sells $1.15m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNU1BkNWI5cjdlVWFkaDZTRHBzaHZwUUpRUUZrYXR4QUtmb2tDeEN0cTFKVG5nblJhdGJNbFoxeTdIejRxcXpzdGFhbVRoUUMyNWxpVVVMeW4xWF92UkNuTHNWb1A2RVBTbFhfX0YzeHptWHlzUmNiS21GdkRQa0p0MVlieV9FY0JYSUd5OU0zcjNHUEtRNGFTbFhkVGFsMldINGhjRDlsWmtrdjQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Initiates Alnylam (ALNY) With Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQRkFrZWEyTUNJdEFFZmZZbVZYX29QUlhfRFhsbzFoRUFJRF8yblVmV3F3cThEd3BIZE5JYmNDQ0drMWhaWVNWRFdITDhuMUV6RHJMUG56UUgxZDhiNnFIUGxXTXJpWUtWa2pzSTRKV2VXSm9fbTZrZzIxS3hBU2h2NUx6RlBzMGlfWWZJR1BsTS1CVnV3TE8tUS1sVGk?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reconsider Alnylam Pharmaceuticals (ALNY) After Recent RNAi Progress And Volatile Price Moves", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOZWVPZ01fbWJBVUdUcHBhZXpJOXRKUWJ5Rml4RkpXOEFWR3dRVTZ4Ym1YZ2pGTlRYS3RudGNXc3BydGd1ajFDdTRoNzV0ajVUUzg1SVZydEtlRUFXcU85MTlHWHd4MmwwaHBoblVCWUtRWEd0WlJnRVpDajk4cVhxN2J2dU1uVS04QWE2MjdaUXY4azNoaGRSc2pfcXp2dU1LSnBNa3ktaFB3NjJ3?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bernstein SocGen lowers Alnylam stock price target on valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOc0w2REtTVU9LZzZXei1BU0tWNWRzZ1dWZFZiLVZ0eTUwRzM4dTZ5Qzk2NnA5VmpOTXdhajNuOHFLRVI2VWZMcEdGUTl3Y2g1TnQwZTFZQWlIZFFucUNRVVY5QUdJRXhOTE44aWFUMUpuYWNSRDlURFY1eWhPN0EyS25LM3c2VUkyT0NDUmEtQ0tiN2JheXVRUnpfYWRmbm5rNTV4RHNmRU1ERlRqcVVIV0R3bW1LYUszSzMyc1RaUS0?oc=5", "source_name": "Investing.com", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Pharmaceuticals (ALNY) Earnings Turn To Profitability Challenges Premium P/E Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Choppy Trading And Rich P/E Multiple", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQTlEyVjFyUC1qZkUzcXJqVW1xOVNCZXZ3QmlXNkNsaTJiWGhkdDc1Q2cwSXVxbDBRcjRBbzZ3TWhoRG00LU00V2RYTlM3bUFUZkxCclhHdzNrSEZYcWU2Y1dZZEVoMzZ3WWZhYko3ZzA3N2pONnpjd3UtaXUtTnRqTDgyM2txWlUwTFE0bTc2ejdPSV84WUl1TTZER21qNUJRbEpRZjBydEV3eVJN?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam (ALNY) slides 4% as valuation concerns linger after recent analyst reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQVE1TcFRfQVc3Si14WnlOOU55a1VIQUN4X0NCdzZHdzZLbTJGZUpkWm9xczFUZ3hIY3dYbTRTYXpzWU9NMGwtUFI2TlgtRDA0OTFwTGhVQUxZWFFJcmhhb2Nfa2JURVBYT1BoTkU0ei1VcjVKUHMxRW54Wm1ObTNYTnh6OVI4eXRKYk9rSTgxVFJIYVdUd3c0cnJ5NHlobW1XaENCTHFVV0RTMHRZQmdqOWUycGRuUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxObVJSVEEzY1NnaHZfZXJpTXJtQWZVV21TMWtWUU4wVkxMcUp3QjFVc3BXeFVPd2lVVGxtVm5jWW9GanBNc1BzcE91MkUwRkl5b19PVFk2UW9ianAyd2dWNmxONERfSjlQSEs1NV9saDhxNy1ZRFA4NFdJck42UVZySU9zLTI2WXVuaTNTSnBZVGNLZFY0LThwRFM3Nnltb2F6N2tadm9wVDBfc3EycWc?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQM0ZQNFJJNGh4cnlyQ1V2aVp4amdWZ013LWhQR3JuSkFVbnFqcXd1REVFRG5TM2wteTRsem1zU0g5M0hyX2Q3SXpQYkhfU1E4czhkMG85U1I0WktHR2xuNjN3bjFzNGtyQTJqQnJ0amFBcEZBV2FWVXZPYUJMSUdzZzQxRnpvYlhzOGRpT3ZHZEp6VTFxNGpCWXFaSnpmaG93OXE1cDRYYXF4T1EtQUtXVUpXNEU4YkZGYlR2R1lGSXJzd29wSE1TN0VZOXZnblFuenNZYjM5NUM?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOamVIbzhDaGtBU3NFOVhYRndfaExDY3pTMUNRVDd1d1Q0SE9qOWpEcUxvNWktU281ZVpPN3lfOEhybjROcXZxdHdjWFlUSUw3WG5EY1JReW9kTnpOSUJuak8tMEpBampWYUxUeW10RWdjR2x1d1dXWjVidm9NRUhoalB1amxQWkF6eE1PQWFDZFo?oc=5", "source_name": "Market source", "published_at": "2025-12-01T08:00:00+00:00", "published_display": "01 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNR0ZOMzF5TjJzbTdMd3N5cWd5ZGtOckVwdXo0WkxhWE5EMjNGSkloMzllZDJJSEdMd0ZpX296RmF1RHA1aFhSUjZpTUpxSTFGcW16VXFlbGpEalpLbVJLSVhPRlVCMnFneGhCN2RJVVV1Z1M1aDhNSU93VkMzV0hBTE1BOG5JY0Z3cDNRSlA5UklGSVhaMW9OOS1xbG5YQQ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2025-10-30T07:00:00+00:00", "published_display": "30 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 60, "sentiment_summary": {"positive": 19, "negative": 7, "neutral": 34, "score": 55, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 6.05, "count": 11}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 267.47, "latest_week": "2026-07-17", "one_week_move": -10.5, "four_week_move": -3.8, "twelve_week_move": -12.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.610601, "market_dynamics_buy_signal": false, "relative_strength": -35.9548, "fair_value_gap": -1.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 39.6387, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.5% over one week, -3.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Investing.com", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Simply Wall Street", "count": 4}, {"label": "Moomoo", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "Quartr", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 11}, {"label": "Guidance", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.5% over one week, -3.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "US2043QAC1 Bond Profile \u2014 Key Metrics"}], "updated_at": "2026-07-23T07:09:26.916602+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}